# PRD: Controlled Expansion Decision for the Tested Feature

## Summary
This document does not recommend immediate release to all users. The available test signal suggests possible upside, but the result is not decision-grade for a full rollout because the experiment was flagged as underpowered and did not meet conventional statistical confidence. The appropriate product requirement is a controlled expansion plan that preserves learning while limiting irreversible exposure.

## Problem Statement
The team wants to expand a feature after a 2-week A/B test with 1,200 users per variant showed a 6% lift in the primary metric at p=0.08. Data science stated the test was underpowered for the claimed effect size and recommended a minimum 6-week run. Product leadership believes the directional result is sufficient and that the business cannot wait.

## Product Decision
Authorize a staged expansion rather than a full-user rollout. The feature may progress only through controlled gates that continue measurement, preserve a holdout or equivalent validation path, and define explicit stop conditions if the observed benefit does not persist.

## Goals
- Capture potential upside without converting an uncertain test result into a full-commitment launch.
- Maintain the ability to validate whether the observed lift is real and durable.
- Create a decision path that balances business urgency with evidence quality.

## Non-Goals
- Declaring the current experiment conclusive.
- Removing measurement safeguards in the name of speed.
- Treating directional movement alone as sufficient proof for universal release.

## Requirements
1. Expansion must be staged, not immediate to all users.
2. Measurement must continue during the staged rollout.
3. The team must preserve a credible way to compare outcomes during expansion.
4. The rollout plan must include explicit progression and rollback criteria.
5. Final universal release requires a documented review of the extended evidence, including whether the initial effect holds under a longer observation window.

## Risks
- The observed lift may be noise rather than a reliable effect.
- A full rollout now would make it harder to resolve whether the feature truly caused the improvement.
- Business urgency may pressure the team into treating weak evidence as settled fact.

## Decision Frame
The decision is not whether the feature looks promising; it is whether the current evidence is strong enough to justify immediate release to all users. It is not. The decision-grade recommendation is a controlled expansion with continued validation, not a universal rollout.

## Unknowns & Evidence Gaps
- Whether the observed 6% lift persists over the longer run recommended by data science.
- Whether the current result is stable enough to reproduce beyond the initial 2-week window.
- Whether business urgency justifies the risk of acting on an inconclusive result.
- What rollout gate would count as sufficient evidence for full release.

## Pass/Fail Readiness
Pass if:
- The organization agrees to a staged rollout instead of an immediate full release.
- Continued measurement and comparison are preserved during rollout.
- Clear advancement and rollback criteria are documented before expansion begins.

Fail if:
- The team intends to release to all users immediately based only on the current test.
- The rollout removes the ability to validate the effect during expansion.
- The team cannot define what additional evidence would be enough to support full launch.

## Recommended Next Artifact
A rollout decision memo that specifies:
- staged release phases
- measurement plan during expansion
- holdout or comparison design
- advancement criteria
- rollback triggers
- final review checkpoint for universal release
